IGF1 and cancer: Besides the PPARγ-dependent insulin-sensitizing effects, which reduce circulating levels of insulin and free IGF1, and downregulate the insulin/IGF1 signaling pathway that plays a role in cancer initiation/progression, other mechanisms, independently of PPARγ activation, could contribute to the antitumor activity of TZDs.